Pharma Equity Group's Significant Decision on Convertible Loans
The Board of Directors of Pharma Equity Group has made a pivotal decision regarding the issuance of convertible loans that could significantly influence the company's future. This strategic move allows Pharma Equity Group to borrow up to DKK 5,842,500, a step that not only aims to strengthen its financial position but also supports the ongoing developments within the company.
Details of the Convertible Loan Issuance
The recently approved convertible loans will replace existing loans amounting to DKK 4,817,500 and a utilized credit facility of DKK 1,025,000. Here are the essential terms and conditions that accompany these convertible loans:
Subordination and Repayment Terms
The loans will be classified as subordinated loan capital, allowing them to be subordinate to the company's other creditors, promoting a more structured financial environment. The nature of these loans means that while they bear an interest rate of 10% per annum, no repayments are required until the conclusion of a specified exercise period, which is set to begin 23 months post-issuance.
Conversion Options and Future Growth
One of the key features of these loans is the lender's right to convert them into shares of the company during a specific exercise period, enhancing stakeholder participation in the company’s growth. The conversion will take place at a predetermined price of DKK 0.20 per share, facilitating further investment and engagement from existing and potential shareholders.
Repaid Convertible Loans and Their Implications
In addition to the new loans, the company will also be repaying previously granted convertible loans amounting to DKK 4,814,500. Just like the newly issued loans, these too have specific terms, including a conversion option available for a similar exercise period. It demonstrates Pharma Equity Group's commitment to maintaining robust financial health while allowing for strategic financial maneuvers to support its subsidiary, Reponex Pharmaceuticals A/S.
Strategic Focus on Drug Development
Pharma Equity Group remains focused on enhancing healthcare solutions through its subsidiary, Reponex Pharmaceuticals A/S. The company prioritizes the development of various drug candidates and innovative medical solutions. With this new capital influx, Pharma Equity Group is poised to propel its drug development projects forward significantly.
Commitment to Sustainable Growth
The effective management of funds garnered from these convertible loans signifies the company’s long-term commitment to driving success within existing medical projects. As opportunities arise, Pharma Equity Group is open to exploring new strategic investments for sustained success and growth in the healthcare sector.
Contact Information
For further inquiries, interested parties may reach out to:
Christian Tange, CEO of Pharma Equity Group A/S, phone: +45 2948 8417
Christian Vinding Thomsen, Chairman of the Board of Directors, phone: +45 2622 7222
Frequently Asked Questions
What is the purpose of the convertible loans issued by Pharma Equity Group?
The convertible loans are intended to strengthen the company's financial position and support the development of drug candidates.
When can lenders convert the loans into shares?
Lenders can exercise their conversion rights 23 months after the loan issuance during a designated exercise period.
How much capital is Pharma Equity Group looking to raise?
Pharma Equity Group aims to raise up to DKK 5,842,500 through the issuance of these convertible loans.
What are the interest rates on the convertible loans?
The loans bear an interest rate of 10% per annum until the end of the exercise period.
Who should I contact for more information?
You can contact Christian Tange, CEO, at +45 2948 8417 or Christian Vinding Thomsen, Chairman, at +45 2622 7222 for more details.
